Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

CONTEXT: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor–positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme. O...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Schroth, Werner, Goetz, Matthew P., Hamann, Ute, Fasching, Peter A., Schmidt, Marcus, Winter, Stefan, Fritz, Peter, Simon, Wolfgang, Suman, Vera J., Ames, Matthew M., Safgren, Stephanie L., Kuffel, Mary J., Ulmer, Hans Ulrich, Boländer, Julia, Strick, Reiner, Beckmann, Matthias W., Koelbl, Heinz, Weinshilboum, Richard M., Ingle, James N., Eichelbaum, Michel, Schwab, Matthias, Brauch, Hiltrud
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3909953/
https://ncbi.nlm.nih.gov/pubmed/19809024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2009.1420
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak